Price$0.72+0.02 (+2.85%)
01:45 PM07:45 PM
News · 26 weeks290%
2026-02-012026-07-26
Mix1690d
- Other7(44%)
- SEC Filings7(44%)
- Insider1(6%)
- Offering1(6%)
Latest news
25 items- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price RequirementGUANGZHOU, China, July 13, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on July 10, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). As a result, the matter has been closed. As previously disclosed, on January 29, 2026, the Company received a notification letter from Nasdaq indicating that the closing bid pri
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Announces Strategic Upgrade Toward Infrastructure for Predictive Healthcare Data and ServicesGUANGZHOU, China, July 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced a strategic upgrade, officially positioning the Company as a foundational infrastructure provider for predictive healthcare data and services. The strategic upgrade reflects the Company's continued evolution from a traditional online healthcare platform toward an artificial intelligence ("AI")-enabled healthcare infrastructure provider. By integrating wearable technologies, AI, physician services, real-world healthcare data, and healthcare payment networks, POM aims to develop an intelligent healthcare ecosys
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Announces ADS Ratio Change to Be Effective on June 22, 2026GUANGZHOU, China, June 17, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced that, as previously announced on May 28, 2026, the ratio change of its American depositary shares (the "ADSs") to Class A ordinary shares from the current ratio of one (1) ADS representing one-sixth (1/6) Class A ordinary share to a new ratio of one (1) ADS representing three (3) Class A ordinary shares (the "ADS Ratio Change") will become effective on June 22, 2026, U.S. Eastern Time (the "Effective Date"). For the Company's ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen re
- SECSEC Form F-6 POS filed by POMDOCTOR LIMITEDF-6 POS - POMDOCTOR Ltd (0001877971) (Subject)
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Announces Plan to Implement ADS Ratio ChangeGUANGZHOU, China, May 28, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to its Class A ordinary shares (the "ADS Ratio Change"), from the current ratio of one (1) ADS representing one-sixth (1/6) Class A ordinary share to a new ratio of one (1) ADS representing three (3) Class A ordinary shares. For the Company's ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen reverse ADS split. A post-effective amendment to the ADS Registration Statement on Form F-6 will be filed with th
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Announces Fiscal Year 2025 Financial ResultsGUANGZHOU, China, May 14, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its financial results for the fiscal year ended December 31, 2025. Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "Fiscal year 2025 marked a year of solid revenue expansion and continued execution of our growth strategy. Both our net revenues and gross profit recorded solid year-over-year increases, by 16.7% and 9.6% respectively, primarily driven by the strong growth of our Internet hospital business, particularly online pharmacy sales as we deepened collaborat
- SECSEC Form 20-F filed by POMDOCTOR LIMITED20-F - POMDOCTOR Ltd (0001877971) (Filer)
- INSIDERSEC Form 3 filed by new insider Bao Wenqing3 - POMDOCTOR Ltd (0001877971) (Issuer)
- SECSEC Form NT 20-F filed by POMDOCTOR LIMITEDNT 20-F - POMDOCTOR Ltd (0001877971) (Filer)
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- INSIDERSEC Form 3 filed by new insider Li Daxue Donnelly3 - POMDOCTOR Ltd (0001877971) (Issuer)
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- INSIDERSEC Form 3 filed by new insider Jing Yuanyuan Crystal3 - POMDOCTOR Ltd (0001877971) (Issuer)
- INSIDERSEC Form 3 filed by new insider Xu Li Jinfuhua3 - POMDOCTOR Ltd (0001877971) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wei Dexiang3 - POMDOCTOR Ltd (0001877971) (Issuer)
- INSIDERSEC Form 3 filed by new insider Luo Guoji3 - POMDOCTOR Ltd (0001877971) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shi Zhenyang3 - POMDOCTOR Ltd (0001877971) (Issuer)
- PRPOMDOCTOR LIMITED Announces Strategic Upgrade, Focusing on "AI + Medical-Grade Smart Wearables" to Build a New Ecosystem for Full-Cycle Chronic Disease ManagementGUANGZHOU, China, March 13, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced a strategic upgrade centered on the core track of "artificial intelligence ("AI") + medical-grade smart wearables + full-cycle chronic disease management". The Company plans to accelerate related technology research and development ("R&D") and scenario-based implementation by leveraging its extensive medical resources and strong compliance capabilities. Over the long run, Pomdoctor aims to build a closed-loop chronic disease management ecosystem integrating hardware, data, algorithms and servi
POM FAQ
5 questionsWhere does POM stock trade?
POMDOCTOR LIMITED (POM) is listed on NASDAQ.What sector and industry is POM in?
POMDOCTOR LIMITED operates in the Consumer Discretionary sector, Other Specialty Stores industry.When did POMDOCTOR LIMITED go public?
POMDOCTOR LIMITED (POM) completed its IPO in 2025.What companies are similar to POM?
Notable peers in the same industry include JD (JD.com Inc.), ULTA (Ulta Beauty Inc.), DKS (Dick's Sporting Goods Inc), FCFS (FirstCash Holdings Inc.), IAA (IAA Inc.). Compare POM side-by-side with any of them on Quantisnow.How can I track POM on Quantisnow?
Quantisnow aggregates POMDOCTOR LIMITED's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow POM to receive live email and push alerts on every new disclosure.